3-PHASE BONE SCANNING AND DIGITAL ARTERIOGRAMS FOR MONITORING VASCULARIZED FIBULAR GRAFTS IN FEMORAL-HEAD NECROSIS

Citation
Kn. Malizos et al., 3-PHASE BONE SCANNING AND DIGITAL ARTERIOGRAMS FOR MONITORING VASCULARIZED FIBULAR GRAFTS IN FEMORAL-HEAD NECROSIS, International angiology, 14(3), 1995, pp. 319-326
Citations number
24
Categorie Soggetti
Cardiac & Cardiovascular System","Peripheal Vascular Diseas
Journal title
ISSN journal
03929590
Volume
14
Issue
3
Year of publication
1995
Pages
319 - 326
Database
ISI
SICI code
0392-9590(1995)14:3<319:3BSADA>2.0.ZU;2-R
Abstract
In this prospective study the authors analysed the prognostic value of monitoring patency of the feedings vessels of the fibular graft, impl anted into the femoral head to treat aseptic necrosis. In 26 patients (29 hips) we applied a three phase Tc-99-MDP Bone Scanning in the seve nth postoperative day. One week later, 18 patients had a digital subtr action angiography of the lateral femoral circumflex artery and its br anches. The patients were followed for average time of 22 months. The average Harris Hip Score of the affected hips improved clinically from 69.5 to 93.5. The vessels were patent prior to the wound closure. Pha se I of the bone scan served as ''radionuclide angiogram'' and demonst rated patent vessels in all about three hips. The digital arteriograms demonstrated patent anastomotic sites in 15 out of 18 hips. Only in f our of the fifteen arteriograms the vessels were visualized throughout the length of the graft. Two of the three hips with negative arteriog rams have also had negative bone scans, both in patients with haemoglo binopathies. None of the patients required further surgery because of failure of the procedure. This study demonstrated that the phase I of the bone scan at the end of the first week postoperatively is very sen sitive means for monitoring the viability of the graft. Digital arteri ograms although more specific, were less sensitive. Early postoperativ e monitoring of the graft viability maintained high predictive value f or the outcome of the treatment in the medium-term.